Germline-Targeting HIV Vaccine Elicits 67% Neutralization Breadth in Primates
Updated
Updated · Nature.com · Jun 30
Germline-Targeting HIV Vaccine Elicits 67% Neutralization Breadth in Primates
1 articles · Updated · Nature.com · Jun 30
Summary
An adjuvanted germline-targeting vaccine produced HIV broadly neutralizing antibodies in outbred nonhuman primates, with bnAb lineages emerging in at least 50% of animals.
Up to 67% neutralization breadth versus a reference bnAb was achieved, and serum from 44% of animals neutralized diverse HIV clinical isolates.
The strongest responder reached serum antibody titers the study said are expected to protect against diverse HIV isolates, while induced antibodies structurally mimicked key human bnAb interactions with HIV Env.
The result marks a proof of principle for a vaccine strategy designed to prime rare bnAb-precursor B cells against HIV's extreme antigenic diversity, though the approach has not yet generated bnAbs in humans.
This new vaccine works in primates, but can it outsmart HIV's rapid evolution in humans?
With the new vaccine neutralizing many HIV strains, what is the plan for the viruses that still escape?
This vaccine is a breakthrough, but what is the timeline for it to become a globally accessible preventative tool?
Broadly Neutralizing Antibodies Induced by Germline-Targeting HIV Vaccine Reach 67% Breadth in Primates
Overview
Recent research has achieved a major breakthrough in HIV vaccine development by using a germline-targeting approach to induce broadly neutralizing antibodies (bNAbs) in nonhuman primates, reaching 67% neutralization breadth. This means the vaccine was able to protect against a wide variety of HIV-1 strains, offering renewed hope for a solution to the virus’s diversity and rapid mutation. The ability to trigger such a broad immune response marks a crucial step forward, as bNAbs can neutralize many strains that typically evade standard immune defenses, moving the field closer to an effective and widely protective HIV vaccine.